NCT03202368View on ClinicalTrials.gov

An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)

PHASE3CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

August 21, 2019

Study Completion Date

August 21, 2019

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab

162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first

Trial Locations (3)

29609

Hopital La Cavale Blanche; Rhumatologie, Brest

59037

Hopital Claude Huriez; Internal Medicine, Lille

68070

Hopital Emile Muller; Medecine Interne, Mulhouse

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03202368 - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) | Biotech Hunter | Biotech Hunter